AI CuratorAI-generated

Research summary · 1 d ago

AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal

Expert Consensus on Factors Influencing Monoclonal Therapy Use in Treatment-Naïve RRMS Patients

An expert panel reached consensus on factors influencing the initiation of monoclonal high-efficacy therapies (HET) for treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS). Specifically, for 82.4% of evaluated statements, factors like high brain lesion load and multiple spinal cord lesions were significant in guiding therapy initiation.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42911241)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: Not reported
Evidence strength: Not graded
Outcome: Not reported

Why it matters

This consensus helps identify key radiological indicators that may guide treatment decisions for RRMS, potentially impacting patient management and outcomes. However, it does not measure clinical outcomes, emphasizing the need for further validation in clinical settings.

What this does not prove

The study relied solely on expert consensus and did not directly assess clinical outcomes, limiting its applicability to real-world scenarios.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 31 · 31 experts responded to both rounds.
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: RRMS
Publication date: 2026-10-22
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: treatment-naïve RRMS patients with high radiological disease activity
Size of effect: Not reported
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidenceDELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis. ↗DOI: 10.1007/s00415-026-14167-4

Supporting passages (12)

findingsConsensus for or against monoclonal HET was reached for 89/108 (82.4%) statements.

subjectsHuman

speciesHuman

sample size31 experts responded to both rounds.

sample size basis31 experts responded to both rounds.

relevant ms typesRRMS

publication date2026-10-22

interventionmonoclonal high-efficacy therapies

populationtreatment-naïve RRMS patients with high radiological disease activity

limitationsTitle: DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis.

peer reviewedPublication types: Journal Article

subjectsMeSH terms: Humans; Multiple Sclerosis, Relapsing-Remitting; Delphi Technique; Female; Male; Adult; Antibodies, Monoclonal; Consensus; Middle Aged; Immunologic Factors; France; Neurologists

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.